This site is intended for Healthcare professionals only.

Zydus Cadila receives final approval from USFDA for Aspirin and extended release Dipyridamole capsules


Zydus Cadila receives final approval from USFDA for Aspirin and extended release Dipyridamole capsules

Mumbai: Pharma major, Zydus Cadila said that company received final approval from the US Food and Drug Administration (USFDA) to market Aspirin and extended release Dipyridamole capsules in the strengths of 25mg/ 200mg.

The Drug is an antiplatelet agent which works in prevention of excessive blood clotting and reduce the risk of strokes in patients who have has or risk to stroke company said in a filing with BSE.

Drugs will be manufactured at its formulations manufacturing facility at Moraiya in Ahmedabad, filing added

The company has more than 140 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.



Source: UNI
0 comment(s) on Zydus Cadila receives final approval from USFDA for Aspirin and extended release Dipyridamole capsules

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted